Stockscreener 앱 받기
5.87
10.65%
-0.70
시간 외 거래:
6.11
0.24
+4.09%
전일 마감가:
$6.57
열려 있는:
$6.55
하루 거래량:
125.90K
Relative Volume:
1.44
시가총액:
$69.14M
수익:
$200.00K
순이익/손실:
$-26.17M
주가수익비율:
-2.2598
EPS:
-2.5976
순현금흐름:
$-18.64M
1주 성능:
-0.84%
1개월 성능:
+24.10%
6개월 성능:
-8.14%
1년 성능:
+36.19%
1일 변동 폭
$5.85
$6.74
1주일 범위
$5.50
$6.74
52주 변동 폭
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
명칭
Clene Inc
전화
801-676-9695
주소
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
5.87 | 77.38M | 200.00K | -26.17M | -18.64M | -2.5976 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-07-18 | 개시 | H.C. Wainwright | Buy |
| 2022-05-02 | 개시 | Canaccord Genuity | Buy |
| 2021-09-28 | 개시 | Oppenheimer | Outperform |
Clene Inc 주식(CLNN)의 최신 뉴스
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Hengan International Group Co (OtherHEGIF) and Clene (CLNN) - The Globe and Mail
Highs Report: What are the analyst revisions for INCYIs Clene Inc stock a good investment in YEAR - baoquankhu1.vn
Treasury Yields: Is Clene Inc Equity Warrant stock undervalued right nowPrice Action & Reliable Breakout Forecasts - baoquankhu1.vn
Nanotechnology Stocks To Watch TodayMarch 17th - MarketBeat
Clene Inc. Announces NIH Subaward Agreement for ALS Expanded Access Protocol – SEC Filing Details - Minichart
Clene Inc. 2025 Annual Report Highlights: Financial Performance, Risk Factors, and Future Outlook - Minichart
Clene 10-K: Revenue $0.2M, EPS $(2.65) — Net Loss $(26.17)M - TradingView
Clene (NASDAQ: CLNN) pushes CNM-Au8 toward accelerated ALS approval - Stock Titan
Clene Secures Third-Year NIH Subaward for ALS Program - TipRanks
Clene Inc. (NASDAQ: CLNN) secures $8M Year 3 ALS grant funding - Stock Titan
Clene (CLNN) Projected to Post Earnings on Monday - MarketBeat
Q1 Earnings Estimate for Clene Issued By HC Wainwright - MarketBeat
Best Nanotechnology Stocks To ResearchMarch 15th - MarketBeat
Promising Nanotechnology Stocks Worth WatchingMarch 14th - MarketBeat
Analysts Offer Insights on Consumer Goods Companies: Clene (CLNN) and American Public Education (APEI) - The Globe and Mail
Clene Inc. (NASDAQ:CLNN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Market Fear: Is Clene Inc a play on infrastructure spendingTrade Signal Summary & Precise Buy Zone Identification - baoquankhu1.vn
Clene (NASDAQ:CLNN) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
CLNN: Canaccord Genuity Reaffirms Buy Rating with $48 Target | C - GuruFocus
Clene (NASDAQ:CLNN) Issues Earnings Results - MarketBeat
Clene (CLNN) Analyst Rating Maintained at "Buy" with $23 Target - GuruFocus
Clene (NASDAQ:CLNN) Receives Buy Rating from D. Boral Capital - MarketBeat
Clene Nanomedicine "CNM-Au8" Market size expansion of Several Folds by 2034 - openPR.com
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Clene (CLNN) Reports FY25 Revenue Beat and Prepares for Key FDA Meeting - GuruFocus
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights - Investing News Network
Biopharmaceutical company Clene Inc (CLNN) recently unveiled its new financing strategy—two potential additional financings totaling over $22 millions have completed structural design. This funding plan will enable the company’s operational cash flow to la - Bitget
Clene reports full-year 2025 results: $200k revenue, $26.2M net loss - TradingView
Clene (NASDAQ: CLNN) narrows 2025 loss and readies accelerated ALS NDA filing - Stock Titan
ALS drug CNM-Au8 links biomarker declines to survival, Clene plans FDA filing - Stock Titan
Top Nanotechnology Stocks To Keep An Eye OnMarch 11th - MarketBeat
Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates - MSN
Nanotechnology Stocks To ConsiderMarch 10th - MarketBeat
Aug Selloffs: What are the analyst revisions for INCYIs Clene Inc. stock a good investment in YEARNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Nanotechnology Stocks To Follow NowMarch 7th - MarketBeat
Aug Movers: Should I set a stop loss on Clene IncExit Point & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Top Nanotechnology Stocks To ResearchMarch 6th - MarketBeat
Institution Moves: How do insiders feel about Clene IncQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Nanotechnology Stocks To Follow TodayMarch 5th - MarketBeat
Best Nanotechnology Stocks Worth Watching – March 3rd - Defense World
CLNN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Promising Nanotechnology Stocks To Follow Today – March 2nd - Defense World
Investor Mood: Is Clene Inc Equity Warrant stock undervalued right nowPortfolio Performance Report & AI Driven Stock Movement Reports - baoquankhu1.vn
Best Nanotechnology Stocks Worth WatchingMarch 3rd - MarketBeat
Top Nanotechnology Stocks To Consider – March 1st - Defense World
Promising Nanotechnology Stocks To Follow TodayMarch 2nd - MarketBeat
Top Nanotechnology Stocks To ConsiderMarch 1st - MarketBeat
Update Recap: Is Clene Inc a play on infrastructure spendingJuly 2025 Retail & Stock Portfolio Risk Management - baoquankhu1.vn
Top Nanotechnology Stocks To Follow TodayFebruary 28th - MarketBeat
CLNN Should I Buy - Intellectia AI
Best Nanotechnology Stocks To Follow NowFebruary 27th - MarketBeat
Clene Inc (CLNN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):